Sign in

CMI Communications

@cmicomms.bsky.social
5.4K followers 413 following 274 posts

ESCMID's open-access journal with companion podcast (Communicable) for all things infectious diseases, clinical microbiology, AMR & stewardship #IDSky #MedSky #EpiSky #ClinMicro 🗞️ www.cmi-comms.org 🎙️ communicable.transistor.fm

PostsRepliesMedia
Reposted by CMI Communications
Rossana Rosa @drrossanarosa.bsky.social · 18/09/2026
Really appreciate the depth that Communicable provides to these studies. It’s context, nuance, applicability, everything 🥰
171
Reposted by CMI Communications
Annie Joseph @anniejoseph.bsky.social · 17/09/2026
So excited for this episode, as we head into the northern hemisphere flu season... the first few cases now coming into our hospital... what do we do... 🤔 🤷 #IDsky #clinmicro
193
CMI Communications @cmicomms.bsky.social · 20/09/2026
🎙️ Just published 'Does oseltamivir harm critically ill patients? The REMAP-CAP results' Hosted by Erin McCreary, PharmD & Josh Davis with invited guests Steve Webb & Steven Tong 🌟 Listen on #Communicable ow.ly/pJAO50ZOfK8 or on #Breakpoints ow.ly/p8Ti50ZOfK9 #IDSky #ViroSky #flu
ow.ly
Communicable E63: Does oseltamivir harm critically ill patients? The REMAP-CAP results | Communicable
1145
CMI Communications @cmicomms.bsky.social · 17/09/2026
📣 New #Communicable / #Breakpoints drops Mon 21 Sep! Erin McCreary, PharmD & Josh Davis are joined by Steve Webb & Steven Tong to discuss REMAP-CAP results suggesting that oseltamivir may harm critically ill patients, while also highlighting the importance and impact of RCTs. #IDSky #ViroSky #flu
0127
Reposted by CMI Communications
ESCMID @escmid.bsky.social · 15/09/2026
💡 Take your clinical trial from concept to completion. Learn how to design, conduct and report a clinical trial through expert-led sessions and workshops covering every stage of the clinical trial journey. Register today: ow.ly/lStL50Zrgqa #IDSky CMI Communications CLARITY_Initiative
011
CMI Communications @cmicomms.bsky.social · 06/09/2026
🎙️ Just published Communicable E62: the 'prose' and cons of the POET trial – early oral antibiotic switch for endocarditis Hosted by Emily McDonald & Josh Davis with invited guests Henning Bundgaard and Sami El-Dalati 🌟 Listen on #Communicable: share.transistor.fm/s/d5eb49ac #IDSky
1122
CMI Communications @cmicomms.bsky.social · 03/09/2026
📣 New #Communicable drops Mon 03 Sep! Emily McDonald & Josh Davis are joined by Henning Bundgaard & Sami El-Dalati to revisit the POET trial and discuss the ‘prose’ and cons of early oral switch for #endocarditis as well as challenges of implementing new evidence against long-standing dogma.
021
CMI Communications @cmicomms.bsky.social · 23/08/2026
🎙️ Just published Communicable E61: We will make you love PK/PD, part 3 Hosted by Amy Legg, Rekha Pai & Angela Huttner with invited guests Amanda Gwee (@amandagwee.bsky.social) & Sebastian Wicha 🌟 Listen on #Communicable: share.transistor.fm/s/c4af55ab #IDSky #clinmicro
share.transistor.fm
Communicable | Communicable E61: We will make you love PK/PD, part 3
064
CMI Communications @cmicomms.bsky.social · 21/08/2026
📣New #Communicable drops Mon 24 Aug. Amy Legg, Rekha Pai & Angela Huttner are back for the third part of the 'We will make you love PK/PD' series! @amandagwee.bsky.social & Sebastian Wicha join them to discuss model-informed precision dosing (#MIPD) that can support individualised dosing decisions.
010
Reposted by CMI Communications
Antibiotic Steward 🅱️C🆔🅿️🌟 @absteward.bsky.social · 13/08/2026
🔥Wow. Our article is published with the legend @bradspellberg.bsky.social 🎉🔥 A journey that started with a simple question: What’s in a name? Today, I’m incredibly grateful to see our article published in @cmicomms.bsky.social EnJoy! #idsky www.cmi-comms.org/article/S295...
cmi-comms.org
What’s in a Name? The Rise of Klebsiella pneumoniae: From Friedländer to Klebs
Within the family of Enterobacteriaceae, few species have evolved in parallel with the history of clinical microbiology and infectious diseases as closely as Klebsiella pneumoniae. First described in ...
0151
Reposted by CMI Communications
CMI Communications @cmicomms.bsky.social · 11/08/2026
📣We rely more & more on #AI for literature review So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review? Not very well: overall #LLM concordance was 0.58-0.75. #IDSky @steventong.bsky.social @seanong.bsky.social cmi-comms.org/article/S295...
cmi-comms.org
A proof-of-concept performance evaluation of six large language models for semiautomated data extraction in a systematic review on infectious diseases clinical trials
Large language models (LLMs) are increasingly being used in the systematic review process. Our objective was to explore data extraction performance of six LLMs from a published systematic review of in...
1128
CMI Communications @cmicomms.bsky.social · 11/08/2026
📣We rely more & more on #AI for literature review So how did 6 large language models compare to humans when extracting data from #RCTs for a systematic review? Not very well: overall #LLM concordance was 0.58-0.75. #IDSky @steventong.bsky.social @seanong.bsky.social cmi-comms.org/article/S295...
cmi-comms.org
A proof-of-concept performance evaluation of six large language models for semiautomated data extraction in a systematic review on infectious diseases clinical trials
Large language models (LLMs) are increasingly being used in the systematic review process. Our objective was to explore data extraction performance of six LLMs from a published systematic review of in...
1128
Reposted by CMI Communications
Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 07/08/2026
New antibiotics may reach patients faster, but approval is only the beginning. The latest REVIVE Antimicrobial Viewpoint by Ursula Theuretzbacher explores why coordinated, adaptive post-approval evidence generation is essential. 🔗 tinyurl.com/yyhuvjff Developed in collab with @cmicomms.bsky.social
153
CMI Communications @cmicomms.bsky.social · 09/08/2026
🎙️ Just published Communicable E60: Quarterly catch-up Hosted by Emily McDonald and Erin McCreary, PharmD 🌟 Listen on #Communicable: share.transistor.fm/s/eac54f9c #IDSky #clinmicro
share.transistor.fm
Communicable | Communicable E60: Quarterly catch-up (August 2026 edition)
042
CMI Communications @cmicomms.bsky.social · 06/08/2026
📣 New #Communicable drops Mon 10 Aug! Emily McDonald and Erin McCreary, PharmD host Quarterly catch-up to review new studies: when post-transplant is PCP likely to occur? How did procalcitonin do in the BALANCE trial? How did cefepime–nacubactam do vs imipenem in cUTI patients?🎙️ #IDSky #clinmicro
061
CMI Communications @cmicomms.bsky.social · 30/07/2026
📣In a prospective nationwide Danish cohort of adults with #VZV #encephalitis: - fever was present at admission in only 39% - early receipt (<6h) of #acyclovir did not reduce mortality or significantly improve other outcomes at 6 months #IDSky #clinmicro #virosky www.cmi-comms.org/article/S295...
cmi-comms.org
Time to acyclovir and outcome of varicella zoster virus encephalitis: A prospective population-based cohort study
Varicella zoster virus (VZV) is a leading cause of encephalitis. This study aimed to examine associations between timing of acyclovir and outcome of patients with VZV encephalitis.
011
CMI Communications @cmicomms.bsky.social · 30/07/2026
📣 In a prospective nationwide Danish cohort of adults with #VZV #encephalitis: - fever was present at admission in only 39% - early receipt (<6h) of #acyclovir did not reduce mortality or significantly improve other outcomes at 6 months #IDSky #virosky #virosky www.cmi-comms.org/article/S295...
cmi-comms.org
Time to acyclovir and outcome of varicella zoster virus encephalitis: A prospective population-based cohort study
Varicella zoster virus (VZV) is a leading cause of encephalitis. This study aimed to examine associations between timing of acyclovir and outcome of patients with VZV encephalitis.
010
Reposted by CMI Communications
CMI Communications @cmicomms.bsky.social · 26/07/2026
🎙️ Just published Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain Hosted by Nav Narayanan & Thomas Tängdén with invited guests, Sören Gatermann, Christian Giske & Amy Mathers 🌟 Listen on #Communicable: share.transistor.fm/s/e2e4ad7e #IDSky #clinmicro
share.transistor.fm
Communicable | Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain
052
CMI Communications @cmicomms.bsky.social · 26/07/2026
🎙️ Just published Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain Hosted by Nav Narayanan & Thomas Tängdén with invited guests, Sören Gatermann, Christian Giske & Amy Mathers 🌟 Listen on #Communicable: share.transistor.fm/s/e2e4ad7e #IDSky #clinmicro
share.transistor.fm
Communicable | Communicable E59: 'Ask me anything' – EUCAST and CLSI leadership explain
052
CMI Communications @cmicomms.bsky.social · 24/07/2026
📣 Q fever poses diagnostic and management challenges. This multinational position paper systematically assesses various countries' responses to #Qfever outbreaks and provides recommendations for future management. #IDSky #clinmicro #episky #Coxiella #zoonosis ow.ly/HeQx50ZsckH
031
Reposted by CMI Communications
Prof Jenny Rohn @jennyrohn.bsky.social · 24/07/2026
Super interesting - great to see more examples that #microbiome imbalances have consequences beyond their immediate niches #UTISky #UTI
021
Reposted by CMI Communications
Angela Huttner @angelahuttner.bsky.social · 24/07/2026
So proud of our @cmicomms.bsky.social editorial fellow Victor Dahl for his gorgeous essay in @thelancetinfdis.bsky.social The Optimism in Front of Us. #IDSky #clinmicro @hoferu.bsky.social www.thelancet.com/journals/lan...
thelancet.com
The optimism in front of us
The world often feels dark when seen through today's headlines. Conflict, division, mistrust, and crisis compete for attention.1 However, working and training in infectious diseases offers a different...
0106
CMI Communications @cmicomms.bsky.social · 24/07/2026
📣 New evidence that #UTI & bacterial vaginosis exist on a continuum of dysbiosis. In this metagenomic study of >600 adults, women with UTI symptoms were nearly 3x more likely to have Nugent #BV. #Lactobacillus crispatus is a protector. #IDSky #UTISky #MicroSky www.cmi-comms.org/article/S295...
cmi-comms.org
Vaginal dysbiosis is associated with urinary symptoms and urinary tract infection: A case–control study
Limited data suggest that bacterial vaginosis (BV) and the composition of the vaginal microbiome may be associated with urinary symptoms and urinary tract infection (UTI). We investigated these relati...
194
CMI Communications @cmicomms.bsky.social · 23/07/2026
📣New #Communicable drops Mon 27 July! Kicking off our new 'Ask me anything' series, hosts Nav Narayanan & Thomas Tängdén invite EUCAST & CLSI leadership – Sören Gatermann, Christian Giske & Amy Mathers – to answer your questions on setting breakpoints, clarifying common misconceptions, and more! 🎙️
032
Reposted by CMI Communications
International Society of Antimicrobial Chemotherapy @isacworld.bsky.social · 20/07/2026
🔬 S. aureus bacteremia therapy webinar 📅 25 Aug 2026 • 13:00 CEST Hear new evidence from DOTS, early oral switch studies & the SNAP trial, plus key unanswered questions in SAB management us02web.zoom.us/webinar/regi... @heiman-wertheim.bsky.social @souhakanj.bsky.social @esgni-escmid.bsky.social
031
CMI Communications @cmicomms.bsky.social · 20/07/2026
📣 The Dutch multidisciplinary guideline on community-acquired #pneumonia is out. Rational, GRADE-based recommendations for the diagnosis & treatment of #CAP requiring hospitalisation. (Sputum cultures & procalcitonin discouraged.) #IDSky #clinmicro www.cmi-comms.org/article/S295...
cmi-comms.org
Management of community-acquired pneumonia in adults: Practice Guideline from The Dutch Working Party on Antibiotic Policy and Dutch Association of Chest Physicians
This guideline is meant for the diagnosis and antibiotic treatment of adult patients without an immunocompromising condition with community-acquired pneumonia (CAP) who present at the hospital.
031
Reposted by CMI Communications
Anita Williams @catanita.bsky.social · 16/07/2026
Infection prevention and control #IPC might not be sexy, but prevention is better than a cure. Therefore those Drs that prevent disease are saving lives, even if it doesn't appear to be very "glamorous" #IDEpi #MedSky
022
CMI Communications @cmicomms.bsky.social · 12/07/2026
🎙️ Just published Communicable E58: Reducing hospital-acquired pneumonia – the HAPPEN trial and how it happened Hosted by Angela Huttner & Josh Davis w/ guests Prof Brett Mitchell, Aline Wolfensberger & Lauren Clack #IDSky #clinmicro Listen on #Communicable: share.transistor.fm/s/825e18f4
075
CMI Communications @cmicomms.bsky.social · 09/07/2026
📣New #Communicable drops Mon 13 July! Angela Huttner & Josh Davis are joined by Prof Brett Mitchell, Aline Wolfensberger & Lauren Clack to discuss the HAPPEN trial, a multicentre RCT showing impressive reductions in hospital-acquired #pneumonia, and the studies that led to it.🎙️ #IDSky #clinmicro
085
CMI Communications @cmicomms.bsky.social · 28/06/2026
🎙️ Just published Communicable E57: We will make you love PK/PD, part 2 – quantitative methods Hosted by Thomas Tängdén and Rekha Pai with invited guests Iris Minichimayr (Austria) & Philip Selby (Australia) 🌟 Listen on #Communicable: share.transistor.fm/s/5edacc5d
120
Reposted by CMI Communications
Global Antibiotic R&D Partnership (GARDP) @gardp.bsky.social · 25/06/2026
🚀We're excited to share our latest Antimicrobial Viewpoint, developed collaboratively with @cmicomms.bsky.social. In 'From fixed courses to flexible care', the authors explore why antifungal treatment durations and routes deserve rethinking. 🔗Read the Viewpoint: revive.gardp.org/from-fixed-c...
revive.gardp.org
From fixed courses to flexible care - reconsidering antifungal treatment duration and route - by Ilana Reinhold, Rosanne Sprute, Jannik Stemler & Oliver A. Cornely
The views and opinions expressed in this article are solely those of the original author(s) and do not necessarily represent those of GARDP, their donors and partners, or other collaborators and contr...
062
CMI Communications @cmicomms.bsky.social · 25/06/2026
📣 New #Communicable drops Monday, 29 June! 'We Will Make You Love PK/PD' series returns with part 2! Thomas Tängdén and Rekha Pai are joined by Iris Minichmayr and Philip Selby to discuss pharmacometrics, PK/PD modelling, and how these quantitative tools can support clinical decision-making. 🎙️
020
CMI Communications @cmicomms.bsky.social · 19/06/2026
📣 Hughes et al perform molecular typing & whole-genome sequencing of #Staph aureus in patients with severe infections. #MSSA CC152 may be a new/under-recognized lineage in Europe causing #PVL positive necrotizing pneumonia & fasciitis. #IDSky #clinmicro #MedSky www.cmi-comms.org/article/S295...
cmi-comms.org
Severe infections in the Netherlands caused by community-acquired methicillin-susceptible Staphylococcus aureus clonal complex 152 carrying PVL, edinB and etE2
To describe severe community-acquired methicillin-susceptible Staphylococcus aureus (MSSA) clonal complex (CC) 152 infections identified in the Netherlands.
012
CMI Communications @cmicomms.bsky.social · 14/06/2026
🎙️ Just published Communicable E56: Frequentist vs Bayesian for clinical trial analysis – 99% probability you’ll want to listen to this Hosted by Emily McDonald & Josh Davis with invited guests Roger Lewis & Ian Marschner 🌟 Listen on #Communicable: share.transistor.fm/s/7ea020d2 #IDSky
0125
CMI Communications @cmicomms.bsky.social · 12/06/2026
📣 If you have questions about fosfomycin, we have answers! Excellent review article by Tiffany Wu, Kalpana Gupta, @erinmccreary.bsky.social, Sarah Turbett & Jacob Lazarus on oral #fosfomycin & how to use it. #IDSky #clinmicro #UTISky #Medsky #Pharmsky www.cmi-comms.org/article/S295...
cmi-comms.org
Oral fosfomycin tromethamine for UTI: Guidance for clinicians
Oral fosfomycin is a guideline-recommended first-line treatment for uncomplicated cystitis. However, fosfomycin has demonstrated lower clinical and/or microbiological cure rates compared with other an...
085
CMI Communications @cmicomms.bsky.social · 11/06/2026
📣 New #Communicable drops Monday, 15 June! Join hosts Josh Davis & Emily McDonald with guests Roger Lewis & Ian Marschner as they demystify Bayesian and frequentist statistical approaches in clinical trials, exploring key differences, common misconceptions, and surprising similarities. 🎙️ #IDSky
1103
CMI Communications @cmicomms.bsky.social · 07/06/2026
🎙️ Just published Communicable E55: Bonus episode – Bundibugyo Ebolavirus outbreak Hosted by Angela Huttner and Anne-Grete Märtson with invited guests Daniel Bausch and Martin Grobusch 🌟 Listen on #Communicable: share.transistor.fm/s/8750e095
143
CMI Communications @cmicomms.bsky.social · 05/06/2026
🎙️ A special bonus episode of #Communicable is coming Monday Angela Huttner & Anne-Grete Märtson talk with Daniel Bausch & Martin Grobusch on how #Bundibugyo ebolavirus differs from Zaire & what to expect in the current outbreak #IDSky #Virosky #clinmicro ow.ly/nm5250Z7ViE
086
CMI Communications @cmicomms.bsky.social · 31/05/2026
🎙️ Just published Communicable E54: ESCMID Global Late Breakers, part 2 Hosted by our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson, Angela Huttner 🌟 Listen on #Communicable: share.transistor.fm/s/a8cc04bb #ESCMIDGlobal2026 #IDSky #clinmicro
075
CMI Communications @cmicomms.bsky.social · 26/05/2026
📣 Note to microbiologists & clinicians who need to isolate #Bordetella spp for antibiogram profiling: Klugherz et al. show that adding #vancomycin to #Regan-Lowe agar doubles the rate of isolation in culture #microsky #clinmicro #idsky #pertussis www.cmi-comms.org/article/S295...
cmi-comms.org
Improving Bordetella pertussis isolation from PCR-positive samples: impact of modified Regan-Lowe agar, sample Ct value and transport time on culture positivity
Pertussis diagnosis relies mainly on PCR tests because of their higher sensitivity and faster results than culture methods. This led to a shortage of clinical isolates for resistance testing and genom...
031
Reposted by CMI Communications
Jacob K McPherson PharmD PhD @jacobkmcpherson.bsky.social · 23/05/2026
A growing focus of my work is PK/PD in infectious diseases and antimicrobial development. @sidpharm.bsky.social Breakpoints @cmicomms.bsky.social Communicable E51 discusses this 🎙️Sootify link here: open.spotify.com/episode/64ZI... #PKPD #Pharmacokinetics #DrugDevelopment #Pharmacology
open.spotify.com
Communicable E51: We will make you love PK/PD, part 1
021
CMI Communications @cmicomms.bsky.social · 19/05/2026
🗞️ Person behind the name: Wolbachia are intracellular Gram-negative bacteria that can manipulate their arthropod hosts' reproduction. Discovered by Hertig and Burt Wollbach, Hertig formally named them after his colleague in 1936. #IDSky #clinmicro #microsky www.cmi-comms.org/article/S295...
cmi-comms.org
“The specimen is never wrong”: the pathologist behind Wolbachia
The genus Wolbachia comprises obligate intracellular, Gram-negative bacteria within the order Rickettsiales and the class Alphaproteobacteria, closely related to Ehrlichia, Anaplasma, and Neorickettsi...
083
CMI Communications @cmicomms.bsky.social · 17/05/2026
🎙️ Just published Communicable E53: ESCMID Global Late Breakers, part 1 Hosted by our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson , Angela Huttner 🌟 Listen on #Communicable: share.transistor.fm/s/e2f3e270 #IDSky #clinmicro #ESCMIDGlobal2026
031
CMI Communications @cmicomms.bsky.social · 14/05/2026
📣 New #Communicable drops Mon, 18 May! Our editors - Erin McCreary, PharmD, Josh Davis, Marc Bonten, Anne-Grete Märtson, Angela Huttner - discuss some of the Late Breaker trials that caught their attention at #ESCMIDGlobal2026, and whether results will change their practice🎙️ #IDSky #clinmicro
086
CMI Communications @cmicomms.bsky.social · 13/05/2026
📣 Migrants & refugees face a higher burden of #AMR but lower access to #healthcare & appropriate #antibiotic use, both difficult to quantify An international expert team has created AdMiRE, a WHO-aligned tool to assess & compare across #migrant populations #IDSky www.cmi-comms.org/article/S295...
cmi-comms.org
AdMiRE study: Development and validation of a WHO-aligned tool to assess healthcare access and antibiotic use among migrant populations in Europe—a multicountry Delphi and psychometric study on behalf...
Antimicrobial resistance (AMR) is a growing global health crisis, threatening medical progress and driving increases in morbidity, mortality, and healthcare costs worldwide [1]. The overuse and misuse...
012
CMI Communications @cmicomms.bsky.social · 08/05/2026
Our collaboration episode with Breakpoints covering the trials from the ESCMID Global session 'The trial run' is out now! share.transistor.fm/s/e2a9aee4 🎙️✨ @erinmccreary.bsky.social @gurujosh.bsky.social @jesusrbano.bsky.social #IDSky #clinmicro
share.transistor.fm
Communicable E52: ESCMID Global Trials, PETER PEN and ASTARTE | Communicable | Episode 52
In this collaborative episode of Breakpoints and Communicable, the hosts revisit the “trial run” session from ESCMID Global, a format designed to facilitate critical discussion of major infectious dis...
1129
Reposted by CMI Communications
Society of Infectious Diseases Pharmacists - SIDP @sidpharm.bsky.social · 04/05/2026
NEW EPISODE COMING SOON! Episode dropping on Friday!
154
CMI Communications @cmicomms.bsky.social · 30/04/2026
📣 New data from the ERADICATE #Saureus bacteremia trial: In patients with renal dysfunction, clinical success was similar with #ceftobiprole vs #daptomycin. Cefto showed no association w/ renal injury relative to dapto. @vancefowler.bsky.social #IDsky #clinmicro www.cmi-comms.org/article/S295...
cmi-comms.org
Ceftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial
Ceftobiprole demonstrated noninferiority to daptomycin for the treatment of Staphylococcus aureus bacteraemia. A range of post hoc exploratory analyses were undertaken to better inform additional key ...
071
CMI Communications @cmicomms.bsky.social · 27/04/2026
📣Never underestimate #TB. Your patient in a high-income country that you diagnosed with ulcerative colitis may have it instead. These authors describe a case of #GI #tuberculosis in our #Debunkingdogma series led by @dremilymcd.bsky.social #IDSky #GISky #clinmicro www.cmi-comms.org/article/S295...
cmi-comms.org
When assumptions lead astray: a diagnostic challenge in inflammatory bowel disease
Global tuberculosis incidence map highlighting endemic regions in 2025 (adapted from WHO data).
0126
CMI Communications @cmicomms.bsky.social · 27/04/2026
📣 #Microsporidiosis has a prevalence of 7% in tested #immunosuppressed patients. Current treatment can be toxic & there is a global shortage. #Nitazoxanide was an effective alternative in this Dutch case series. #Enterocytozoon #diarrhea #GISky #IDSky #microsky www.cmi-comms.org/article/S295...
cmi-comms.org
Nitazoxanide for Enterocytozoon bieneusi infection treatment in renal transplant recipients: case series
Enterocytozoon bieneusi microsporidiosis is an opportunistic infection in immunocompromised patients. There is a lack of established treatment strategies. In this report, we present an overview of the...
011